Summary

A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation. The findings, presented at the European Society for Medical Oncology ( ESMO ) Congress by Dr.

AI summaries can be wrong sometimes—always verify important details using the source article.